Inactive Instrument

News BioTime, Inc. Nyse

Equities

US09066L1052

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development	Apr. 01	BU
Lineage Cell Therapeutics : Immediate Report	Mar. 24	PU
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium	Mar. 18	BU
LINEAGE CELL THERAPEUTICS, INC. - RG6501 PHASE 1/2A CLINICAL STUDY 24 MONTH RESULTS TO BE FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT	Mar. 14	AQ
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit	Mar. 13	BU
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting	Mar. 11	BU
Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting	Mar. 11	CI
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Samuel George A. III	Mar. 10	PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Cukkey Brian M	Mar. 10	PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Howe Jill Ann	Mar. 10	PU
Lineage Cell Therapeutics : FORM S-3-Registration Statements	Mar. 10	PU
Lineage Cell Therapeutics : Annual report which provides a comprehensive overview of the company for the past year	Mar. 10	PU
Transcript : Lineage Cell Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q4 Revenue $8.9M, vs. Street Est of $2.8M	Mar. 07	MT
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 07	BU
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024	Feb. 29	BU
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury	Feb. 13	BU
Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury	Feb. 13	CI
LINEAGE CELL THERAPEUTICS ANNOUNCES CLOSING OF $14.0 MILLION REGISTERED DIRECT OFFERING	Feb. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioTime, Inc. Nyse

Equities

US09066L1052

Summary

Filters